CD40 ligation impedes lymphoblastoid B cell proliferation and S-phase entry

Leukemia Research

Volumn 22, Issue 4, 1998, Pages 319-327

  Bishop, Julie Y ^b   Schattner, Elaine J ^b   Friedman, Steven M ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b NONE

Author keywords

B cells; CD40; Cell cycle; Growth inhibition; Lymphoma

Indexed keywords

CD40 ANTIGEN; MEMBRANE ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIGATION; LYMPHOBLASTOID CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; B-LYMPHOCYTES; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYMPHOCYTE ACTIVATION; S PHASE; TUMOR CELLS, CULTURED;

EID: 0032052784     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(97)00173-2     Document Type: Article

References (47)

1. [1] Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989;8:1403.
2. [2] Kansas GS, Wood GS, Tedder TF. Expression, distribution and biochemistry of human CD39: role in activation-associated homotypic adhesion of lymphocytes. J Immunol 1991;146:2235.
3. [3] Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells as observed after an improved isolation method. PNAS USA 1992;87:7698.
4. [4] Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4 + T cells that induces contact-dependent B cell differentiation (help). J Exp Med 1992;175:1091.
5. [5] Lederman S, Yellin MJ, Cleary AM, Pernis A, Inghirame G, Cohn LE, Covey LR, Lee JJ, Rothman P, Chess L. T-BAM/ CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J Immunol 1994;152:2163.
6. [6] Sarma V. Lin Z, Clark L, Rust BM, Tewari M, Noelle RJ, Dixit VM. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem 1995;2705:12343.
7. [7] Banchereau J, Rousset F, Growing human B lymphocytes in the CD40 system. Nature 1991;353:678.
8. [8] Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan ICM. Mechanism of antigen-driven selection in germinal centers. Nature 1989;342:929.
9. [9] Parry S, Hasbold J, Holman M, Klaus GGB. Hypercross-linking surface IgM or IgD receptors on mature B cells induces apoptosis that is reversed by costimulation with IL-4 and anti-CD40. J Immunol 1994;152:2821.
10. [10] Hartley SB, Cooke MP, Fulcher DA, Harris AW, Cory S, Basten A, Goodnow CC. Elimination of self-reactive B lymphoctes proceeds in 2 stages: arrested development and cell death. Cell 1993;72:325.
11. [11] Kamesaki H, Zwiebel JA, Reed JC, Cossman J. Role of bcl-2 and IL-5 in the regulation of anti-IgM-induced growth arrest and apoptosis in immature B cell lines. J Immunol 1994;152:3294.
12. [12] Durie FH, Foy TM, Masters SR, Laman JD, Noele RJ. The role of CD40 in the regulation of humoral and cell mediated immunity. Immunol Today 1994;15:406.
13. [13] Bergman MC, Attrep JF, Grammer AC, Lipsky PE. Ligation of CD40 influences the function of human Ig secreting B cell hybridomas both positively and negatively. J Immunol 1996;156:3118.
14. [14] Oehm A, Behrmann I, Falk W, Pawlita M, Maier G. Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, Ponstring H, Krammer PH. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J Biol Chem 1992;267:10709.
15. [15] Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(FAS/CD95). Nature 1995;373:438.
16. [16] Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-FAS) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747.
17. [17] Chu K, Niu X, Williams LT. A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. PNAS USA 1995;92:11894.
18. [18] Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449.
19. [19] Schattner E, Elkon KE, Yoo D, Tumang J, Krammer P, Crow MK, Friedman SM. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. Blood 1995;88:1375.
20. [20] Cleary AM, Fortune SM, Yellin MJ, Chess L, Lederman S. Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. J Immunol 1995;155:3329.
21. [21] Schall T, Lewis M, Koller K, Lee A, Rice G, Wong G, Gatanaga G, Lentz R, Raab H, Kohr W, Goeddel D. Molecular cloning and expression of a receptor for human necrosis factor. Cell 1990;61:361.
22. [22] Sugarman BJ, Aggarwal BB, Mass PE, Figari IS, Palladino MAJ, Shepard HM. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985;230:943.
23. [23] Itoh N, Nagata S. A novel protein domain required for apoptosis: mutational analysis of human FAS antigen. J Biol Chem 1993;268:10932.
24. [24] Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993;74:845.
25. [25] Rudert F, Roos M, Forbes L, Watson J. Apoptosis in L929 cells expressing a CD40/Fas chimeric receptor: dissociation of stimulatory from inhibitory death signalling functions. Biochem Biophys Res Commun 1994;204:1102.
26. [26] Hess S, Engelmann H. A novel function of CD40: Induction of cell death in transformed cells. J Exp Med 1996;183:159.
27. [27] Nilsson K, Klein G, Henle W, Henle G. The establishment of lymphoblastoid cell lines from adult and fetal human lymphoid tissue and its dependence on Epstein-Barr virus. Int J Cancer 1971;8:443.
28. [28] Steinitz M, Klein G. Comparison between growth characteristics of an Epstein-Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro. PNAS USA 1975;72:3518.
29. [29] Rowe DT, Rowe M, Evan G, Wallace LE, Farrell PJ, Rickinson AB. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J 1986;5:2599.
30. [30] Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickenson AB. Epstein-Barr virus (EBV)-associated lymphoproliferalive disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991;173:147.
31. [31] Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ. Human Epstein-Barr Virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B.-17 Scid/Scid mice. J Exp Med 1996;183:1215.
32. [32] Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt Lymphoma: Expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell 1987;49:161.
33. 3H]-thymidine incorporation assay. J Immunol Methods 1994;170(2):211.
34. [34] Gray GD, Wickstrom E. Evaluation of anchorage-independent proliferation in tumorigenic cells using the redox dye alamar-Blue™. Biotechniques 1996;21:780.
35. [35] Ledbetter JA, Shu G, Gallagher M, Clark EA. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell specific antigen BP50 (CDw40). J Immunol 1987;138:788.
36. [36] Armitage RJ, Fanslow WC, Stockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR, Clark EA, Smith CA, Grabstein KH, Cosman D, Spriggs MK. Molecular and biological characterization of a murine ligand for CD40. Nature 1992;357:80.
37. [37] Arpin C, Dechanet J, Kooten CV, Merville P, Grouard G, Briere F, Banchereau J, Liu Y. Generation of memory B cell and plasma cells in vitro. Science 1995;268:720.
38. [38] Noelle R, Ledbetter JA, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today 1992;13:431.
39. [39] Valle A, Zuber CE, Defrance T, Djossou O, De Rie M, Banchereau J. Activation of human B lymphocytes through CD40 and interleukin 4. Eur J Immunol 1989;19:1463.
40. [40] Yellin MJ, Sinning J, Covey LR, Sherman W, Lee JJ, Glickman-Nir E, Sippel KC, Rogers J, Cleary AM, Parker M, Chess L, Lederman S. T lymphocyte T cell-B cell-activating molecule/ CD40L molecules induce normal B cells or chronic lymphocytic leukemia B cell to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994;153:666.
41. [41] Morio T, Hanissian S, Gena RS. Characterization of a 23-kDa protein associated with CD40. Proc Nall Acad Sci USA 1995;92:1163.
42. [42] Faris M, Gaskin F, Parsons JT, Fu SM. CD40 signaling pathway: Anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylaled proteins including protein tyrosine kinase lyn, fyn, and syk and the appearance of a 28-kD tyrosine phophorylated protein. J Exp Med 1994;179:1923.
43. [43] Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988;335:256.
44. [44] Murphy WJ, Funakoshi S, Beckwith M, Rushing SE, Conley DK, Armitage RJ, Fanslow WC, Rager HC, Taub DD, Ruscetti FW, Longo DL. Antibodies to CD40 prevent Epstein-Barr Virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. Blood 1995;86:1946.
45. [45] Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I, Armitage RJ, Fanslow WC, Spriggs MK, Murphy WJ. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83:2787.
46. [46] Santos-Argumedo L, Gordon J, Heath AW, Howard M. Antibodies to murine CD40 protect normal and malignant B cells from induced growth arrest. Cell Immunol 1994;156:272.
47. [47] Heath AW, Chang R, Harada N, Santos-Argumedo L, Gordon J. Hannum C, Campbell D, Shanafelt AB, Clark EA, Torres R. Floward M. Antibodies to murine CD40 stimulate normal B lymphocytes to inhibit proliferation of B lymphomas. Cell Immunol 1993;152:468.